Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812]

Ann Oncol. 2024 Apr 13:S0923-7534(24)00076-0. doi: 10.1016/j.annonc.2024.03.002. Online ahead of print.
No abstract available

Publication types

  • Published Erratum